Amylin: The Overlooked Pancreatic Peptide That Helps Control Blood Sugar in Diabetes
Amylin — a peptide hormone co-released with insulin — is deficient in both type 1 and type 2 diabetes, and its synthetic replacement pramlintide improves blood sugar control and promotes weight loss when added to insulin therapy.
Quick Facts
What This Study Found
Amylin plays three key roles in glucose homeostasis: suppressing post-meal glucagon release, delaying gastric emptying, and activating satiety centers in the brain to reduce caloric intake. Type 1 diabetes patients have absent amylin response to meals, while insulin-requiring type 2 patients have diminished response proportional to beta-cell impairment.
Pramlintide, the synthetic amylin analog, demonstrated significant HbA1c reductions in both type 1 and type 2 diabetes when added to insulin therapy, with favorable effects on body weight — an important advantage since insulin itself tends to promote weight gain. Key risks include increased hypoglycemia when combined with insulin and gastrointestinal side effects including nausea.
Key Numbers
Amylin absent in T1D; diminished in insulin-requiring T2D; pramlintide reduces A1C and body weight as adjunct to insulin
How They Did This
Narrative review of amylin physiology, pathophysiology in diabetes, and clinical evidence for pramlintide use in type 1 and type 2 diabetes. Published in a diabetes education journal.
Why This Research Matters
Diabetes treatment has traditionally focused almost entirely on insulin, but this review highlights that diabetes involves multiple hormonal deficiencies — including amylin. Replacing amylin alongside insulin provides a more complete hormonal restoration that improves glucose control and addresses the weight gain problem that plagues insulin therapy. Understanding amylin's role has also influenced the development of newer combination approaches like cagrilintide (an amylin analog) paired with semaglutide.
The Bigger Picture
This review places amylin in the broader context of multi-hormonal diabetes management. The concept of amylin deficiency has gained renewed interest with the development of cagrilintide (a long-acting amylin analog) being combined with semaglutide (CagriSema) for obesity and diabetes treatment. Understanding amylin's foundational role helps explain why these combination approaches are so promising.
What This Study Doesn't Tell Us
Narrative review, not systematic; no specific effect sizes reported; predates newer amylin analog developments; aimed at educators rather than researchers.
Questions This Raises
- ?Could long-acting amylin analogs like cagrilintide overcome the practical barriers that limited pramlintide adoption?
- ?Does amylin replacement early in type 2 diabetes slow beta-cell decline?
- ?How does amylin's satiety effect compare to GLP-1 agonists, and what's the benefit of combining both?
Trust & Context
- Key Stat:
- 3 mechanisms of blood sugar control Amylin suppresses glucagon, slows stomach emptying, and activates satiety centers — all absent or diminished in diabetes
- Evidence Grade:
- This is a narrative review in a diabetes education journal that summarizes established physiology and clinical trial data. It serves as a reference-grade overview rather than presenting new primary evidence.
- Study Age:
- Published in 2015, this review covers well-established amylin physiology and pramlintide clinical data that remain accurate. However, the field has since advanced with newer amylin analogs like cagrilintide entering clinical trials in combination with GLP-1 agonists.
- Original Title:
- Role of Amylin in Type 1 and Type 2 Diabetes.
- Published In:
- The Diabetes educator, 41(1 Suppl), 47S-56S (2015)
- Authors:
- Hieronymus, Laura, Griffin, Stacy
- Database ID:
- RPEP-02663
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is amylin and why haven't I heard of it?
Amylin is a peptide hormone made by the same beta cells in your pancreas that produce insulin. It's released alongside insulin every time you eat. Amylin helps control blood sugar by slowing digestion, suppressing glucagon, and making you feel full. It gets less attention than insulin because it was only discovered in 1987, but it's an important part of normal blood sugar regulation that goes missing in diabetes.
Is pramlintide the same as the amylin in CagriSema?
Not exactly. Pramlintide (Symlin) is a shorter-acting amylin analog that's injected before each meal. Cagrilintide, the amylin component in CagriSema, is a newer long-acting amylin analog that only needs weekly dosing and is being combined with semaglutide for obesity and diabetes treatment. Both work through amylin pathways, but cagrilintide represents a significant advancement in convenience.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-02663APA
Hieronymus, Laura; Griffin, Stacy. (2015). Role of Amylin in Type 1 and Type 2 Diabetes.. The Diabetes educator, 41(1 Suppl), 47S-56S. https://doi.org/10.1177/0145721715607642
MLA
Hieronymus, Laura, et al. "Role of Amylin in Type 1 and Type 2 Diabetes.." The Diabetes educator, 2015. https://doi.org/10.1177/0145721715607642
RethinkPeptides
RethinkPeptides Research Database. "Role of Amylin in Type 1 and Type 2 Diabetes." RPEP-02663. Retrieved from https://rethinkpeptides.com/research/hieronymus-2015-role-of-amylin-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.